The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

The European Commission has approved BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy as a first-line treatment for oesophageal squamous cell carcinoma (ESCC ...

28,064 people played the daily Crossword recently. Can you solve it faster than others?28,064 people played the daily Crossword recently. Can you solve it faster than others? Warren Buffett Sends ...

BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum ...

The FDA has approved BeiGene’s Tevimbra (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of unresectable or metastatic ...